Medulloblastoma is a common and aggressive type of brain tumor in children, consisting of four molecular subgroups. Traditional methods of treatment with surgery, radiotherapy and chemotherapy result in an incomplete response with serious side effects. Immunotherapy using the blockade of immune checkpoints such as PD-1, PD-L1 and CTLA4 has increased its prominence in solid tumor therapies. However, its application has been disappointing in brain tumors. Thus, alternative and poorly described immunological checkpoints could be revealed as interesting targets for medulloblastoma therapy.